{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:36:07Z","timestamp":1793050567457,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00198-026-08126-y","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:34:03Z","timestamp":1784943243000},"page":"2507-2515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three months of abaloparatide treatment rapidly improves bone formation and density: implications for orthopedic preoperative bone health optimization"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1965-5144","authenticated-orcid":false,"given":"Nicholas B.","family":"VanDerwerker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Mosiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bernatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"8126_CR1","doi-asserted-by":"publisher","unstructured":"(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646\u2013650. https:\/\/doi.org\/10.1016\/0002-9343(93)90218-E","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"8126_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286110","author":"ZQ Fan","year":"2023","unstructured":"Fan ZQ, Yan XA, Li BF, Shen E, Xu X, Wang H, Zhuang Y (2023) Prevalence of osteoporosis in spinal surgery patients older than 50 years: a systematic review and meta-analysis. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0286110","journal-title":"PLoS One"},{"key":"8126_CR3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/BRS.0000000000004618","volume":"48","author":"PA Anderson","year":"2023","unstructured":"Anderson PA, Binkley NC, Bernatz JT (2023) Bone health optimization (BHO) in spine surgery. Spine (Phila. Pa. 1976) 48:782\u2013790","journal-title":"Spine (Phila. Pa. 1976)"},{"key":"8126_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.arth.2019.03.044","volume":"34","author":"JT Bernatz","year":"2019","unstructured":"Bernatz JT, Brooks AE, Squire MW, Illgen RI 2nd, Binkley NC, Anderson PA (2019) Osteoporosis is common and undertreated prior to total joint arthroplasty. J Arthroplast 34:1347\u20131353. https:\/\/doi.org\/10.1016\/j.arth.2019.03.044","journal-title":"J Arthroplast"},{"key":"8126_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/2192568217743727","volume":"8","author":"BT Bjerke","year":"2018","unstructured":"Bjerke BT, Zarrabian M, Aleem IS, Fogelson JL, Currier BL, Freedman BA, Bydon M, Nassr A (2018) Incidence of osteoporosis-related complications following posterior lumbar fusion. Glob Spine J 8:563\u2013569. https:\/\/doi.org\/10.1177\/2192568217743727","journal-title":"Glob Spine J"},{"key":"8126_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5371\/HP.2024.36.4.260","volume":"36","author":"M Daher","year":"2024","unstructured":"Daher M, Mekhael E, El-Othmani MM (2024) Total hip arthroplasty in patients with hip osteoporosis: a narrative review. Hip Pelvis 36:260\u2013272. https:\/\/doi.org\/10.5371\/HP.2024.36.4.260","journal-title":"Hip Pelvis"},{"key":"8126_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.10.003","author":"AK Emara","year":"2024","unstructured":"Emara AK, Turan O, Pasqualini I et al (2024) Preoperative osteoporosis is associated with increased health care utilization and compromised pain and function improvement after primary total hip arthroplasty: a prospective cohort analysis. J Arthroplast. https:\/\/doi.org\/10.1016\/j.arth.2024.10.003","journal-title":"J Arthroplast"},{"key":"8126_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/21514593231216553","author":"KJ Jeray","year":"2023","unstructured":"Jeray KJ, Williams SA, Wang Y, Pearman L, Pyrih N, Singla K, Han BH, Bukata SV (2023) Bone health management in elective orthopaedic surgery: a claims-based observational study. Geriatr Orthop Surg Rehabil. https:\/\/doi.org\/10.1177\/21514593231216553","journal-title":"Geriatr Orthop Surg Rehabil"},{"key":"8126_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jocd.2019.07.013","volume":"22","author":"PA Anderson","year":"2019","unstructured":"Anderson PA, Morgan SL, Krueger D, Zapalowski C, Tanner B, Jeray KJ, Krohn KD, Lane JP, Yeap SS, Shuhart CR, Shepherd J (2019) Use of bone health evaluation in orthopedic surgery: 2019 ISCD official position. J Clin Densitom 22:517\u2013543. https:\/\/doi.org\/10.1016\/j.jocd.2019.07.013","journal-title":"J Clin Densitom"},{"key":"8126_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2106\/JBJS.19.00999","volume":"102","author":"A Kadri","year":"2020","unstructured":"Kadri A, Binkley N, Hare KJ, Anderson PA (2020) Bone health optimization in orthopaedic surgery. J Bone Joint Surg Am 102:574\u2013581. https:\/\/doi.org\/10.2106\/JBJS.19.00999","journal-title":"J Bone Joint Surg Am"},{"key":"8126_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausalwomen with osteoporosis a randomized clinical trial. JAMA 316:722\u2013733. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"8126_CR12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/JBMR.4719","volume":"37","author":"E Czerwinski","year":"2022","unstructured":"Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B (2022) The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial. J Bone Miner Res 37:2435\u20132442. https:\/\/doi.org\/10.1002\/JBMR.4719","journal-title":"J Bone Miner Res"},{"key":"8126_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4877","volume":"38","author":"EM Lewiecki","year":"2023","unstructured":"Lewiecki EM, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, Silverman S, Cardona J, Nattrass SM, Binkley N, Annett M, Pearman L, Mitlak B (2023) Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study. J Bone Miner Res 38:1404\u20131414. https:\/\/doi.org\/10.1002\/jbmr.4877","journal-title":"J Bone Miner Res"},{"key":"8126_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/BRS.0000000000004618","volume":"48","author":"PA Anderson","year":"2023","unstructured":"Anderson PA, Binkley NC, Bernatz JT (2023) Bone health optimization (BHO) in spine surgery. Spine (Phila Pa 1976) 48:782\u2013790. https:\/\/doi.org\/10.1097\/BRS.0000000000004618","journal-title":"Spine (Phila Pa 1976)"},{"key":"8126_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.TJEM.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu H (2018) User\u2019s guide to correlation coefficients. Turk J Emerg Med 18:91. https:\/\/doi.org\/10.1016\/J.TJEM.2018.08.001","journal-title":"Turk J Emerg Med"},{"key":"8126_CR16","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/S00198-018-04819-1","volume":"30","author":"R Eastell","year":"2019","unstructured":"Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM (2019) Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE. Osteoporos Int 30:667\u2013673. https:\/\/doi.org\/10.1007\/S00198-018-04819-1","journal-title":"Osteoporos Int"},{"key":"8126_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/JBMR.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642. https:\/\/doi.org\/10.1002\/JBMR.3641","journal-title":"J Bone Miner Res"},{"key":"8126_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0B013E31828826DD","author":"S Ohtori","year":"2013","unstructured":"Ohtori S, Inoue G, Orita S et al (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). https:\/\/doi.org\/10.1097\/BRS.0B013E31828826DD","journal-title":"Spine (Phila Pa 1976)"},{"key":"8126_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, Khosla S, de Papp A, Mitlak B, Cauley JA, McCulloch CE, Eastell R, Bouxsein ML (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672\u2013682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8126_CR20","unstructured":"FDA qualifies total hip bone mineral density (BMD) as surrogate endpoint for osteoporosis drug development | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-qualifies-total-hip-bone-mineral-density-bmd-surrogate-endpoint-osteoporosis-drug-development. Accessed 10 May 2026"},{"key":"8126_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/JBMR.4433","volume":"37","author":"R Eastell","year":"2021","unstructured":"Eastell R, Vittinghoff E, Lui LY, McCulloch CE, Pavo I, Chines A, Khosla S, Cauley JA, Mitlak B, Bauer DC, Bouxsein M, Black DM (2021) Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH\u2010ASBMR SABRE project. J Bone Miner Res 37:29. https:\/\/doi.org\/10.1002\/JBMR.4433","journal-title":"J Bone Miner Res"},{"key":"8126_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-023-01344-5","author":"T Sone","year":"2023","unstructured":"Sone T, Ohnaru K, Sugai T, Yamashita A, Okimoto N, Inoue T, Matsumoto T (2023) The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial. Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-023-01344-5","journal-title":"Arch Osteoporos"},{"key":"8126_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","volume":"30","author":"NB Watts","year":"2019","unstructured":"Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F (2019) Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 30:1187\u20131194. https:\/\/doi.org\/10.1007\/s00198-019-04890-2","journal-title":"Osteoporos Int"},{"key":"8126_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0749-0690(02)00074-5","volume":"19","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Bilezikian JP (2003) The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 19:415\u2013432. https:\/\/doi.org\/10.1016\/S0749-0690(02)00074-5","journal-title":"Clin Geriatr Med"},{"key":"8126_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jbmr.4243","volume":"36","author":"DW Dempster","year":"2021","unstructured":"Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH (2021) Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res 36:644\u2013653. https:\/\/doi.org\/10.1002\/jbmr.4243","journal-title":"J Bone Miner Res"},{"key":"8126_CR26","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMOA1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMOA1607948","journal-title":"N Engl J Med"},{"key":"8126_CR27","doi-asserted-by":"publisher","unstructured":"MR M, A G, S B, MA B, JP B, A D-P, BL L, JY R, JR Z, SM W, L K, J M, YC Y, C L, HG B (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:248\u2013259. https:\/\/doi.org\/10.1056\/NEJMOA1305224","DOI":"10.1056\/NEJMOA1305224"},{"key":"8126_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(25)00319-5","volume":"14","author":"BZ Leder","year":"2026","unstructured":"Leder BZ, Ramchand SK, Jordan M, Ryan S, Patnaik A, Lee H, Tsai JN (2026) 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol 14:216. https:\/\/doi.org\/10.1016\/S2213-8587(25)00319-5","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08126-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08126-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:01:44Z","timestamp":1793048504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08126-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8126"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08126-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in The ATOM and wearABLe studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Per 45 CFR 46.104, this analysis is exempt from human subject research regulation. This project involved no direct contact with human or animal subjects. For this post-hoc analysis, we were provided fully de-identified data from the clinical studies ATOM (NCT03512262) and wearABLe (NCT04064411). These studies were conducted in full compliance of human research regulations, and all participants had provided written informed consent prior to participation, including consent for the use of their de-identified data in post-hoc analyses. For this type of study, formal consent is not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both clinical studies, ATOM (NCT03512262) and wearABLe (NCT04064411), provided the underlying data for the present analysis. The ATOM and wearABLe clinical studies were approved by local Institutional Review Boards (IRBs) or central ethics committees in the respective participating countries.","order":2,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Paul A. Anderson served as a senior author of this paper. Dr. Anderson has served as a paid consultant for Radius Health, Inc. Radius Health, Inc. did not provide any funding for this project or otherwise influence this project in any way. Additionally, Dr. Paul A. Anderson has obtained royalties or licenses from Regeneration technologies, has served as a paid consultant for and has received payment for education activities from Amgen, serves on the Data Safety Monitoring Board for Orthofix, and is president of the International Society for Bone Densitometry. Dr. Neil Binkley and Diane Krueger have received grants or contracts from GE Healthcare and Medimaps. None of these conflicts are relevant to the research reported here. Nicholas VanDerwerker, Samuel Mosiman, and James Bernatz declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}